Comparison of short versus long-term leuprolide acetate--human menopausal gonadotrophin hyperstimulation in in-vitro fertilization patients.
The use of leuprolide acetate for at least 10 days beginning in the mid-luteal phase prior to initiating human menopausal gonadotrophin (HMG) stimulation has been fairly successful in preventing cancellations for premature luteinization and allowing retrieval of more oocytes, which in turn provide more embryos for cryopreservation. However, it is theoretically possible that the long-term use of leuprolide may have some adverse effect on either pregnancy rates or on mean survival after cryopreservation and thawing. Recently, a short 3 day regimen of a gonadotrophin-releasing hormone agonist, buserelin effectively prevented premature luteinization during HMG stimulation. The present study indicated that substitution of a 3 day course of leuprolide acetate also effectively prevented premature luteinization but was less expensive, required statistically fewer ampoules of HMG and much less leuprolide.
Check
J H
JH
University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Cooper Hospital/University Medical Center, Department of Obstetrics and Gynecology, Camden.
Nowroozi
K
K
Chase
J S
JS
D000328:Adult; D002064:Buserelin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D005307:Fertilization in Vitro / Q000379:methods*; D006801:Humans; D016729:Leuprolide / Q000008:administration & dosage* / Q000494:pharmacology; D008183:Luteal Phase / Q000187:drug effects; D008596:Menotropins / Q000008:administration & dosage* / Q000494:pharmacology; D011446:Prospective Studies; D011897:Random Allocation
D008596:Menotropins; D016729:Leuprolide; D002064:Buserelin